GlassScriptPhysician profile
John Windsor Esther
NPI 1174056121
$14,070.55
in general payments reported to CMS, 2019-2025
39 companies · $8,174 in 2025
The $8,174 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $171 · 2024: $5,725 · 2025: $8,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,328 · Food and Beverage: $2,289 · Honoraria: $2,275 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,327.50 |
| Food and Beverage | $2,288.59 |
| Honoraria | $2,275.00 |
| Education | $179.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $11,718.76 | 2024-2025 | Besremi |
| Janssen Biotech, INC. | $290.70 | 2024-2025 | Tecvayli, Talvey, Carvykti |
| Novartis Pharmaceuticals Corporation | $289.86 | 2024-2025 | |
| Pfizer INC. | $235.08 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $167.83 | 2023-2025 | Libtayo |
| Daiichi Sankyo INC. | $152.19 | 2023-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $147.04 | 2024-2025 | Enhertu, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $94.36 | 2023-2024 | Keytruda |
| Iovance Biotherapeutics, INC. | $74.97 | 2025 | Amtagvi |
| Genzyme Corporation | $69.39 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $63.32 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $59.27 | 2024-2025 | Onivyde, Tazverik |
| Jazz Pharmaceuticals INC. | $58.02 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $57.17 | 2024-2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $54.70 | 2024-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $53.20 | 2025 | Tevimbra |
| Exelixis INC. | $52.67 | 2024-2025 | Cabometyx |
| Lilly USA, LLC | $47.64 | 2024-2025 | Retevmo |
| Recordati_rare_diseases_inc. | $39.80 | 2024-2025 | Sylvant |
| Astellas Pharma US INC | $31.63 | 2023-2024 | Xtandi, Xospata |
| Sobi, INC | $31.49 | 2024 | |
| Emd Serono, INC. | $28.25 | 2023-2025 | Tepmetko |
| Karyopharm Therapeutics INC. | $17.90 | 2025 | Xpovio |
| Morphosys, US INC. | $16.79 | 2024 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $16.76 | 2025 | Opdivo |
| Sirtex Medical INC | $16.57 | 2024 | Sir-Spheres Microspheres |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Genmab U.S., INC. | $15.70 | 2023 | Epkinly |
| Caris Mpi, INC. | $15.45 | 2025 | Mi Cancer Seek |
| Eisai INC. | $15.10 | 2024 | |
| Celgene Corporation | $14.71 | 2024 | Reblozyl |
| Puma Biotechnology, INC. | $14.28 | 2025 | |
| Adc Therapeutics America, INC. | $14.26 | 2024 | |
| Incyte Corporation | $13.71 | 2023 | Monjuvi |
| Springworks Therapeutics, INC. | $13.56 | 2024 | Ogsiveo |
| Dendreon Pharmaceuticals LLC | $13.16 | 2024 | Provenge |
| Pharmacosmos Therapeutics INC. | $13.12 | 2024 | Cosela |
| Gilead Sciences, INC. | $13.08 | 2024 | |
| Glaxosmithkline, LLC. | $13.07 | 2024 | Zejula, Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Esther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.